New study shows increase in Welsh breastfeeding rates during pandemic medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Research finds link between parental health literacy with Covid test results in kids miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
An Active Building that generates, stores and releases its own solar power is providing the village of Khuded in rural India with a reliable supply of electricity for the first time.
Advancing the Diagnosis and Treatment of Ovarian Cancer
insights from industryDr. Marcos Quintela VasquezResearch and Development Innovation OfficerRBGO Research Group
In this interview, News-Medical talks to Dr. Marcos Quintela Vasquez about the work he is conducting regarding the diagnosis and treatment of ovarian cancer in partnership with CEAT and Porvair Sciences.
Please tell us about CEAT, your project aims and how the group of partners was assembled?
The Cluster for Epigenomic and Antibody Drug Conjugate (ADC) Therapeutics (CEAT) is a Swansea University-led partnership between key multi-national players Glaxo Smith Kline (GSK), Cytiva and Bruker, together with UK-based partners Porvair Sciences Ltd, Axis Bio, and BiVictriX. The CEAT project, jointly funded by the Welsh European Funding Office and collaborating partners, is designed to enable partners to deliver advances in epigenetic and ADC-based ovarian cancer therapeutics.